Study finds that anti-diabetic medication can prevent the long-term effects of maternal obesity

In a study to be presented today at the Society for Maternal-Fetal Medicine's annual meeting, The Pregnancy Meeting, in Dallas, Texas, researchers will report findings that show that short therapy with the anti-diabetic medication Pioglitazone can prevent the long term effects of maternal obesity on offspring.

This study, Pioglitazone Therapy in Exposed to Maternal Obesity, is the first step in the long term goal of preventing metabolic syndrome and obesity in children secondary to maternal obesity. The data proposes a potential role for drugs that activate peroxisome proliferator-activated receptors in the prevention of metabolic syndrome in adult offspring of obese mothers.

"Obesity in children, which is on the rise, predisposes them to lifelong diseases such as diabetes, high lipid levels, hypertension and cardiac diseases," said Egle Bytautiene, MD, PhD, with The University of Texas Medical Branch, Obstetrics and Gynecology, Galveston, Texas, and one of the study's authors. "A large part of obesity in children is programmed during and our study shows that a drug used to treat diabetes in adults can prevent the long term effects of on the offspring, even when used for a short period of time after birth."

Bytautiene and her colleagues placed mice on a high fat diet for three months prior to, and during pregnancy. The resulting pups were weaned to a regular diet. Pups were randomly selected to receive Pioglitazone or a placebo. Treatment was given once daily from 10 to 12 weeks of age. Immediately before and after the treatment period, the offspring were weighed, their visceral adipose tissue was evaluated using computed-tomography, blood was collected for fasting glucose and triglyceride analysis, and intraperitoneal glucose tolerance tests were performed. The results showed Pioglitazone therapy significantly reduced body weight gain. There was also a trend towards lower visceral adipose tissue gain and improvement in glucose and triglyceride levels.

This is one of the first experimental studies investigating the impact of postnatal treatment in the offspring of obese dams. Its implications on the long-term metabolic status of the offspring are immense.

In addition to Bytautiene, the study was conducted by Arshag Kalanderian, Monica Longo and George R. Saade, University of Texas Medical Branch, Obstetrics & Gynecology, Galveston, Texas; Nicola Abate, University of Texas Medical Branch, Internal Medicine, Galveston, Texas; and Igor Patrikeev and Massoud Motamedi, University of Texas Medical Branch, Center for Biomedical Engineering, Galveston, Texas.

Provided by Society for Maternal-Fetal Medicine

5 /5 (1 vote)
add to favorites email to friend print save as pdf

Related Stories

Inflammation may link obesity and adverse pregnancy outcomes

Jan 10, 2012

A number of different immunological mechanisms ensure the successful establishment and maintenance of pregnancy. Imbalance in these mechanisms is associated with adverse pregnancy outcomes. In a review published in Advances in ...

Recommended for you

Don't let high altitude ruin your holiday trip

10 hours ago

(HealthDay)—When you're planning your holiday get-away, don't forget to factor high altitude into your vacation sports—such as skiing or hiking, a sports medicine specialist cautions.

User comments

Adjust slider to filter visible comments by rank

Display comments: newest first

dogbert
not rated yet Feb 11, 2012
I suppose the next step is to place chubby babies on diabetic medication?

Crazy.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.